Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $7.0 million.

  • Atara Biotherapeutics' Operating Expenses fell 8865.64% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.7 million, marking a year-over-year decrease of 4573.04%. This contributed to the annual value of $212.4 million for FY2024, which is 2537.12% down from last year.
  • Atara Biotherapeutics' Operating Expenses amounted to $7.0 million in Q3 2025, which was down 8865.64% from $14.4 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Operating Expenses ranged from a high of $95.5 million in Q1 2022 and a low of $7.0 million during Q3 2025
  • For the 4-year period, Atara Biotherapeutics' Operating Expenses averaged around $61.5 million, with its median value being $64.2 million (2023).
  • The largest annual percentage gain for Atara Biotherapeutics' Operating Expenses in the last 5 years was 126.78% (2025), contrasted with its biggest fall of 8865.64% (2025).
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Operating Expenses stood at $75.8 million in 2022, then dropped by 15.24% to $64.2 million in 2023, then decreased by 29.99% to $45.0 million in 2024, then plummeted by 84.37% to $7.0 million in 2025.
  • Its Operating Expenses stands at $7.0 million for Q3 2025, versus $14.4 million for Q2 2025 and $59.3 million for Q1 2025.